350 related articles for article (PubMed ID: 33669204)
1. The Role of IGF/IGF-1R Signaling in Hepatocellular Carcinomas: Stemness-Related Properties and Drug Resistance.
Ngo MT; Jeng HY; Kuo YC; Diony Nanda J; Brahmadhi A; Ling TY; Chang TS; Huang YH
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669204
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical Expression of Insulin-Like Growth Factor-1 Receptor and Its Association with Clinicopathological Parameters in Hepatocellular Carcinoma.
Peloso Maia ML; Albuquerque RM; do Carmo Silva SD; Lima CX; Costa Diniz PH; Vieira Teixeira Vidigal P
Oncology; 2024; 102(6):494-502. PubMed ID: 37989120
[TBL] [Abstract][Full Text] [Related]
3. The emerging role of insulin and insulin-like growth factor signaling in cancer stem cells.
Malaguarnera R; Belfiore A
Front Endocrinol (Lausanne); 2014; 5():10. PubMed ID: 24550888
[TBL] [Abstract][Full Text] [Related]
4. A Yes-Associated Protein (YAP) and Insulin-Like Growth Factor 1 Receptor (IGF-1R) Signaling Loop Is Involved in Sorafenib Resistance in Hepatocellular Carcinoma.
Ngo MT; Peng SW; Kuo YC; Lin CY; Wu MH; Chuang CH; Kao CX; Jeng HY; Lin GW; Ling TY; Chang TS; Huang YH
Cancers (Basel); 2021 Jul; 13(15):. PubMed ID: 34359714
[TBL] [Abstract][Full Text] [Related]
5. The Role of Nuclear Insulin and IGF1 Receptors in Metabolism and Cancer.
Werner H; Sarfstein R; Laron Z
Biomolecules; 2021 Apr; 11(4):. PubMed ID: 33918477
[TBL] [Abstract][Full Text] [Related]
6. COCH predicts survival and adjuvant TACE response in patients with HCC.
Wang C; Ding ZW; Zheng CG; Wang S; Li ZH; Zhang ZM; Pan J; Wang J; Yang C
Oncol Lett; 2021 Apr; 21(4):275. PubMed ID: 33732351
[TBL] [Abstract][Full Text] [Related]
7. Long-term effectiveness of population-wide multifaceted interventions for hepatocellular carcinoma in Taiwan.
Liao SH; Chen CL; Hsu CY; Chien KL; Kao JH; Chen PJ; Chen TH; Chen CH
J Hepatol; 2021 Jul; 75(1):132-141. PubMed ID: 33689789
[TBL] [Abstract][Full Text] [Related]
8. Factors predicting long-term outcomes of early-stage hepatocellular carcinoma after primary curative treatment: the role of surgical or nonsurgical methods.
Kuo MJ; Mo LR; Chen CL
BMC Cancer; 2021 Mar; 21(1):250. PubMed ID: 33685409
[TBL] [Abstract][Full Text] [Related]
9. Clinical Implications of HBV PreS/S Mutations and the Effects of PreS2 Deletion on Mitochondria, Liver Fibrosis, and Cancer Development.
Liang YJ; Teng W; Chen CL; Sun CP; Teng RD; Huang YH; Liang KH; Chen YW; Lin CC; Su CW; Tao MH; Wu JC
Hepatology; 2021 Aug; 74(2):641-655. PubMed ID: 33675094
[TBL] [Abstract][Full Text] [Related]
10. IGF-1R down regulates the sensitivity of hepatocellular carcinoma to sorafenib through the PI3K / akt and RAS / raf / ERK signaling pathways.
Cai W; Ma Y; Song L; Cao N; Gao J; Zhou S; Tang X
BMC Cancer; 2023 Jan; 23(1):87. PubMed ID: 36698167
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of BACH1 mediated by IGF2 facilitates hepatocellular carcinoma growth and metastasis via IGF1R and PTK2.
Xie M; Sun M; Ji X; Li D; Chen X; Zhang B; Huang W; Zhang T; Wang Y; Tian D; Xia L
Theranostics; 2022; 12(3):1097-1116. PubMed ID: 35154476
[No Abstract] [Full Text] [Related]
12. Signaling pathways in liver cancer: pathogenesis and targeted therapy.
Xue Y; Ruan Y; Wang Y; Xiao P; Xu J
Mol Biomed; 2024 May; 5(1):20. PubMed ID: 38816668
[TBL] [Abstract][Full Text] [Related]
13. In silico and network pharmacology analysis of fucosterol: a potent anticancer bioactive compound against HCC.
Singh K; Kumar P; Singh AK; Singh N; Singh S; Tiwari KN; Agrawal S; Das R; Singh A; Ram B; Tripathi AK; Mishra SK
Med Oncol; 2024 Apr; 41(6):130. PubMed ID: 38676780
[TBL] [Abstract][Full Text] [Related]
14. The importance of protein domain mutations in cancer therapy.
Chitluri KK; Emerson IA
Heliyon; 2024 Mar; 10(6):e27655. PubMed ID: 38509890
[TBL] [Abstract][Full Text] [Related]
15. The Role of Type 2 Diabetes Mellitus-Related Risk Factors and Drugs in Hepatocellular Carcinoma.
Mai Y; Meng L; Deng G; Qin Y
J Hepatocell Carcinoma; 2024; 11():159-171. PubMed ID: 38268569
[TBL] [Abstract][Full Text] [Related]
16. Tumor Microenvironment Composition and Related Therapy in Hepatocellular Carcinoma.
Li Z; Zhang Z; Fang L; Zhao J; Niu Z; Chen H; Cao G
J Hepatocell Carcinoma; 2023; 10():2083-2099. PubMed ID: 38022729
[TBL] [Abstract][Full Text] [Related]
17. Hepatocellular Carcinoma: Up-regulated Circular RNAs Which Mediate Efficacy in Preclinical
Weidle UH; Nopora A
Cancer Genomics Proteomics; 2023; 20(6):500-521. PubMed ID: 37889063
[TBL] [Abstract][Full Text] [Related]
18. Overview of hepatocellular carcinoma: from molecular aspects to future therapeutic options.
Panneerselvam S; Wilson C; Kumar P; Abirami D; Pamarthi J; Reddy MS; Varghese J
Cell Adh Migr; 2023 Dec; 17(1):1-21. PubMed ID: 37726886
[TBL] [Abstract][Full Text] [Related]
19. Translocation of IGF-1R in endoplasmic reticulum enhances SERCA2 activity to trigger Ca
Li Y; Li K; Pan T; Xie Q; Cheng Y; Wu X; Xu R; Liu X; Liu L; Gao J; Yuan W; Qu X; Cui S
Acta Pharm Sin B; 2023 Sep; 13(9):3744-3755. PubMed ID: 37719369
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
